Patients with type 2 diabetes mellitus have a greater than normal risk of developing atherosclerotic vascular diseases. Higher than normal plasma concentrations of lipoprotein (a) [Lp(a)] have been associated with premature atherosclerosis in several studies.
Objective
To determine the concentrations of lipids, lipoproteins, and Lp(a) in 107 type 2 diabetic patients, and the distribution of apolipoprotein (a) [apo(a)] phenotypes for this group, and to compare the results found with results for health-subjects.
Results
Plasma concentrations of cholesterol, triglycerides, and apolipoprotein B in the diabetics were significantly higher than those in control subjects. Diabetic patients had slightly lower Lp(a) concentrations than did nondiabetic subjects, but these differences were not statistically significant. Distribution; of Lp(a) concentrations both in type 2 diabetic patients and in control subjects were markedly skewed, the highest prevalences being of low values.
Conclusion
Distributions of apo(a) phenotypes for patients with type 2 diabetes mellitus and controls were remarkably alike. Smaller isoforms were similarly prevalent for the two populations, as were the null, single-band and double-band apo(a) phenotypes.
HoeflerGHarnoncourtFPaschkeEHirtlWPfeifferDKostnerG. Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis1988;8: 398–401.
2.
RosengrenAWilhelmsenLErickssonERisbergBWedelH. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ1990; 301: 1248–1251.
3.
BergK. A new serum type system in man: the Lp(a) system. Acta Pathol Microbiol Scand1963; 59: 369–389.
BoerwinkleELeffertCCLinJLacknerCChiesaGHobbsH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest1992; 90: 52–60.
6.
KraftHGKochlSMenzelHJSandholzerCUtermannG. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet1992; 90: 220–230.
7.
GenestJJJrMartin-MunleySSMcNamaraJR. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation1992;85: 2025–2033.
8.
WooJLauELawCWK. Hypertension, Lp(a) and apolipoprotein A–1 as risk factor for stroke in the Chinese. Stroke1991; 22: 203–208.
9.
WHO Study Group. Diabetes Mellitus.Geneva: WHO; 1985.
10.
Comisión de Lipidos y Lipoproteinas de la Sociedad Española de Quimica Clinica. Protocolo para la obtención de especimenes en las determinaciones de lipidos y lipoprotelnas. Quim Clin1989; 8: 349–351.
11.
AllainCCPoonLSChanCSGRichmondWFuPC. Enzymatic determination of total serum cholesterol. Clin Chem1974; 20: 470–475.
12.
Van HandelEZilversmitDB. Micromethod for the direct determination of serum triglycerides. J Lab Clin Med1957; 50: 152–157.
13.
KostnerGMMolinariEPichlerP. Evaluation of a new HDL2/HDL3 quantitation method based on precipitation with polyethylene glycol. Clin Chim Acta1985; 148: 139–147.
14.
FriedewaldWTLevyRIFredricksonDS. Estimate of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem1972; 18: 499–502.
15.
WeinstockNBartholomeMSeidelD. Determination of apolipoprotein A–1 by kinetic nephelometry. Biochim Biophys Acta1981; 663: 279–288.
KraftHGDieplingerHHoyeEUtermannG. Lp(a) phenotyping by immunoblotting with polyclonal and monoclonal antibodies. Arteriosclerosis1988;8: 212–216.
18.
RainwaterDLMacCluerJWSternMPVandebergJLHaffnerSM. Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein (a) sizeDiabetes1994; 43: 942–946.
19.
SandholzerCHallmanDMSahaNSigurdssonGLacknerCCsaszarAEffects of the apolipoprotein(a) size polymorphism of the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet1991; 86: 607–614.
20.
PfeiferMABrunzellJDBestJDJudzwitschRGHalterJB. The response of plasma triglyceride, cholesterol, and lipoprotein lipase to treatment in type 2 diabetic subjects without familial hypertriglyceridemia. Diabetes1983;32: 525–531.
21.
RamirezLCPachecoC ArauzLacknerCAlbrightGAdamsBVRaskinP. Lipoprotein(a) levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med1992; 117: 42–47.
22.
SnidermanAShapiroSMarpoleDSkinnerBTengBKwiterovichPOJr. Association of coronary atherosclerosis with hyperapobetalipoproteinemia. Proc Natl Acad Sci USA1980; 77: 604–609.
23.
SchernthanerGKostnerGMDieplingerHPragerRMuhehauserI. Apolipoproteins (A–1, A–II, B): lipoprotein(a), lipoprotein and lecithin cholesterol acyltransferase activity in diabetes mellitus. Atherosclerosis1983;49: 277–293.
24.
JovenJVilellaE. Serum levels of lipoprotein(a) in patients with well controlled non-insulin diabetes mellitus [letter]. JAMA1991; 265: 1113–1114.
25.
LevitskyLLScanuAMGouldSH. Lipoprotein(a) levels in black and white children and adolescents with IDDM. Diabetes Care1991; 14: 283–287.
26.
VelhoGErlichDTurpinE. Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes Care1993; 16: 742–747.
27.
HaffnerSMMoralesPASternPMGrubetMK. Lp(a) concentrations in NIDDM. Diabetes1992; 41: 1267–1272.
28.
GarberAJVinicAICrespinSR. Detection and management of lipid disorders in diabetic patients. Diabetes Care1992; 15: 1068–1074.
UtermannGKraftHGMenzelHJHopferweiserTSeitzC. Genetics of the quantitative Lp(a) trait. I. Relation of Lp(a) glycoprotein phenotypes Lp(a) lipoprotein concentration in plasma. Hum Genet1988; 78: 41–46.
31.
KlausenICSchmidtEBLervangHHGerdesLUDitzelJFaergemanO. Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin dependent diabetes mellitus. Eur J Clin Invest1992; 22: 538–541.
